For example, off-target activation could lead to myotonia (NaV1.4), atrial fibrillation and cardiac arrest (NaV1.5), seizures (NaV1.2) or neuropathies (NaV1.7 and NaV1.8). This evidence concerns the gene SCN9A and neuropathy.